hVIVO PLC EUR3.2m Venn contract with global pharma client

TIDMHVO

hVIVO PLC

17 January 2023

hVIVO plc

("hVIVO" or the "Company")

EUR3.2m contract for Venn Life Sciences with global pharmaceutical client

For provision of pharmacokinetic and programming services

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its consultancy services division, Venn Life Sciences ("Venn") , has signed a contract with a major global pharmaceutical client worth EUR3.2m over two years.

The contract commences in January 2023, with the Venn team in Breda providing dedicated complex clinical pharmacokinetics ("PK") consultancy and programming services to this global pharmaceutical client on a number of drug development programmes across multiple therapeutic areas, to study the absorption, distribution and excretion of drugs within the body.

Venn has nearly 30 experts dedicated to providing PK and programming services to clients and has been a trusted partner to the pharma industry for over 25 years. These services cover a diverse range of trials and therapeutic areas ranging from traditional phase I trials to more complex and challenging trials, such as oncology and ATMP (Advanced Therapy Medicinal Product) trials. Venn is a leader in providing fully integrated drug development services from early drug discovery to clinical trials. Its offering includes drug development consultancy, clinical trial design and execution services with expertise and capabilities in CMC (Chemistry, Manufacturing and Controls), Non-Clinical, Clinical Pharmacology and Development, Statistics, Study Design and Methodology, Data Management, Medical Writing and Regulatory Affairs. These combined services enable Venn to provide its clients with a complete end-to-end service on all stages of their drug development programmes, from the early planning phase to final execution. Venn has offices in Breda (Netherlands) and Paris (France).

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "The consultancy work included in this two-year contract highlights the continued expansion of our pharmacokinetic and programming services as part of Venn's integrated drug development services provision. Venn's outstanding expertise and reputation in the industry over the past 25 years makes them a go-to partner. In addition, for infectious disease products, hVIVO and Venn have also been able to conduct projects from discovery to Phase II Challenge Studies, something no one else can offer."

Dr Katsuhiro Mihara, Head of Clinical Development of Venn Life Sciences, commented: "This contract is a great example of Venn's ability to deliver on long term PK and programming projects. We have worked closely with hVIVO to identify ways to leverage this strong client base, to drive both upselling and cross-selling opportunities, and find even greater synergies between the two integrated clinical services businesses."

For further information please contact:

 
 hVIVO plc                                                           [phone] 
 Yamin 'Mo' Khan, Chief Executive 
  Officer 
  Stephen Pinkerton, Chief Financial 
  Officer 
 
 Liberum Capital (Nominated Adviser and 
  Joint Broker)                                                      [phone] 
 Ben Cryer, Edward Mansfield, Phil Walker, 
  Will King 
 
 finnCap plc (Joint Broker)                                          [phone] 
 Geoff Nash, Charlie Beeson, Nigel Birks, 
  Harriet Ward (ECM) 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                             [phone] 
 Anthony Farrell, Niall Gilchrist 
 
 Walbrook PR (Financial PR & IR)             [phone] or [e-mail] 
  Stephanie Cuthbert / Phillip                    [phone] / [phone] 
  Marriage /                                                                        082 / 
  Louis Ashe-Jepson                                                  [phone] 
 
 

Notes to Editors

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABRGDBUDBDGXL

(END) Dow Jones Newswires

January 17, 2023 02:00 ET (07:00 GMT)